CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
EnglishVALABREGA, Giorgio
Risultati 1 - 20 di 50 (tempo di esecuzione: 0.001 secondi).
| Titolo | Data di pubblicazione | Autore(i) | |
|---|---|---|---|
| 1 | Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. | 2016 | Erriquez, J; Olivero, M; Mittica, G; Scalzo, Ms; Vaira, M; De Simone, M; Ponzone, R; Katsaros, D; Aglietta, M; Calogero, R; Di Renzo, Mf; Valabrega, G |
| 2 | Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study | 2008 | MONTEMURRO F; REDANA S; NOLE' F; DONADIO M; JACOMUZZI ME; VALABREGA G; VIALE G; SAPINO A; AGLIETTA M |
| 3 | Veliparib: a new therapeutic option in ovarian cancer? | 2019 | Ghisoni, Eleonora; Giannone, Gaia; Tuninetti, Valentina; Genta, Sofia; Scotto, Giulia; Aglietta, Massimo; Sangiolo, Dario; Mittica, Gloria; Valabrega, Giorgio |
| 4 | Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer. | 2010 | Montemurro F; Rossi V; Nolè F; Redana S; Donadio M; Martinello R; Verri E; Valabrega G; Rocca MC; Jacomuzzi ME; Viale G; Sapino A; Aglietta M. |
| 5 | Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer | 2007 | VALABREGA G; MONTEMURRO F; AGLIETTA M |
| 6 | Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial | 2008 | MONTEMURRO F; REDANA S; VALABREGA G; MARTINELLO R; AGLIETTA M; PALMIERO R |
| 7 | Trastuzumab-based combination therapy for breast cancer | 2004 | MONTEMURRO F; VALABREGA G; AGLIETTA M |
| 8 | Trastuzumab treatment in breast cancer | 2006 | MONTEMURRO F; VALABREGA G; AGLIETTA M |
| 9 | Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities. | 2011 | Montemurro F; Redana S; Geuna E; Milani A; Rossi V; Martinello R; Valabrega G; Aglietta M. |
| 10 | Trastuzumab Beyond Disease Progression: Case Closed? | 2009 | Valabrega G; Aglietta M; Montemurro F |
| 11 | TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. TOP2A as marker of response to PLD in ovarian cancer | 2015 | Erriquez, J.; Becco, P.; Olivero, M.; Ponzone, R.; Maggiorotto, F.; Ferrero, A.; Scalzo, M.S.; Canuto, E.M.; Sapino, A.; Verdun di Cantogno, L.; Bruna, P.; Aglietta, M.; Di Renzo, M.F.; Valabrega, G. |
| 12 | TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers | 2019 | Ghisoni, Eleonora; Maggiorotto, Furio; Borella, Fulvio; Mittica, Gloria; Genta, Sofia; Giannone, Gaia; Katsaros, Dionyssios; Sciarrillo, Alberto; Ferrero, Annamaria; Sarotto, Ivana; Erriquez, Jessica; Di Renzo, Maria Flavia; Aglietta, Massimo; Valabrega, Giorgio |
| 13 | The 41st Annual Meeting of the American Society of Clinical Oncology. Orlando, FL, USA, 13-17 May, 2005 | 2005 | MONTEMURRO F; VALABREGA G; GARETTO L; ALIBERTI S; GRIGNANI G; ORTEGA C; LEONE F; PONZONE R; AGLIETTA M |
| 14 | TGFalpha expression impairs Trastuzumab-induced HER2 downregulation | 2005 | VALABREGA G; MONTEMURRO F; SAROTTO I; PETRELLI A; RUBINI P; TACCHETTI C; AGLIETTA M; COMOGLIO PM; GIORDANO S |
| 15 | Secondary cytoreductive surgery, hyperthermic intraperitoneal intraoperative chemotherapy, and chemotherapy alone: A retrospective comparison of alternative approaches in relapsed platinum sensitive ovarian cancer | 2016 | Marocco, F.; Vaira, M.; Milani, A.; Genta, S.; Maggiorotto, F.; Magistris, A.; Cinquegrana, A.; Robella, M.; De Simone, M.; Aglietta, M.; Ponzone, R.; Valabrega, G |
| 16 | Role of trastuzumab in the management of HER2-positive metastatic breast cancer. | 2010 | Milani A;Montemurro F;Gioeni L;Aglietta M;Valabrega G |
| 17 | Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era | 2008 | Montemurro F; Redana S; Viale G; Sanna G; Donadio M; Valabrega G; del Curto B; Bottini A; Botti G; Paolo dei Tos A; Jacomuzzi ME; Di Bonito M; Danese S; Clavarezza M; Kulka J; Di Palma S; Durando A; Sapino A; Aglietta M |
| 18 | A Retrospective Analysis of the Activity and Safety of Oral Etoposide in Heavily Pretreated Metastatic Breast Cancer Patients. | 2015 | Valabrega G;Berrino G;Milani A;Aglietta M;Montemurro F |
| 19 | Reprogramming T-cells for adoptive immunotherapy of ovarian cancer | 2018 | Genta, Sofia; Ghisoni, Eleonora; Giannone, Gaia; Mittica, Gloria; Valabrega, Giorgio |
| 20 | Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007 | 2007 | MONTEMURRO F; REDANA S; VALABREGA G; AGLIETTA M |
Nome completo:
VALABREGA, Giorgio
Copyright © 2019